| GTO ID | GTC3296 |
| Trial ID |
NCT05672173
|
| Disease |
Chronic Lymphocytic Leukemia
|
Richter Syndrome
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017 |
| Location approved | US, Japan, EU, Switzerland, UK, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation |
| Year | 2023 |
| Country | United States |
| Company sponsor | City of Hope Medical Center |
| Other ID(s) | 22040|NCI-2022-10247|22040|P30CA033572 |